Immuron's Travelan ® Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets Key Highlights: • US Travelan ® sales continue an upward trend with a 95% increase in the Third Quart

Travelan Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets

Australia, April 23, 2018: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian microbiome biopharmaceutical

company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory

mediated and infectious diseases, is today pleased to announce the sales results of its commercially available, over-the-counter

gastrointestinal and digestive health supplement Travelan , for the third fiscal quarter ending March 31, 2018.

robust sales growth continued throughout the third quarter both in Australia and the US, with combined sales to March 31, 2018

reaching AUD$1.37M marking a 40% increase on the same period last year.

third quarter saw US Travelan sales surge ahead, achieving AUD$166K and marking a +95% increase compared to

the AUD$85K sales figure achieved for the same period last year. This resulted in year-to-date (YTD) US sales of AUD$501K for

nine-months ended March 31, 2018, compared to AUD$180K sales for the same period last year. These figures demonstrate

that Immuron is on track to more than double its 2017 sales of Travelan in the US market by the end of the

Australia, Travelan continues its sales momentum achieving AUD$863K for the nine-months ended March 31, 2018,

representing a +9% increase on the same period last year.

healthy growth of Travelan sales can be attributed to our continued trade marketing program within major Australian

pharmacies and our distribution in the USA through over 193 Passport Health Travel Clinics. An additional 39 clinics within the

Passport Health Travel network will commence distribution of Travelan in the fourth quarter, providing even

further opportunities to bolster US sales.

Marketing Manager Mr. David Montgomery, said,

addition to the growing distribution of Travelan , the ground-breaking US Department of Defense (DoD) research

report which was announced in January 2018 has generated excitement within the investor market and the travel medicine community.

primary goal of this US DoD program was to investigate Travelan 's immunological reactivity with pathogenic

bacteria including Campylobacter, Enterotoxigenic E-coli and Shigella.

The tested bacterial isolates

originated from the Armed Forces Research Institute of Medical Sciences (AFRIMS) in Bangkok, Thailand an overseas laboratory of

the Walter Reed Army Institute of Research (WRAIR) library of infectious diseases. The pathogenic bacteria were retrieved from

infected personnel deployed in Bhutan, Cambodia, Nepal and Thailand over a 20-year period.

research findings have provided further data to build on existing clinical trial results for Travelan and have

provided us with a powerful message to take to the market that the antibodies in Travelan were able to bind

and reactive to all 180 strains of bacteria tested demonstrating the broad spectrum antimicrobial potential of the product .

Limited (ASX: IMC, NASDAQ: IMRN), is an Australian microbiome biopharmaceutical company focused on developing and commercializing

orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has

a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and

sells Travelan for the prevention of Travelers' Diarrhea and its lead clinical candidate, IMM-124E,

is in Phase II clinical trials for Non-Alcoholic Steatohepatitis (NASH), Severe Alcoholic Hepatitis (SAH) and Pediatric

Non-Alcoholic Fatty Liver Disease (NAFLD). Immuron's second clinical stage asset, IMM-529, is targeting Clostridium

difficile Infections (CDI). These products together with the Company's other preclinical immunotherapy pipeline

products targeting immune-related diseases currently under development, will meet a large unmet need in the global immunotherapy

more information visit: http://www.immuron.com

is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travellers'

diarrhoea. Travelan is a highly purified tabletised preparation of hyper immune bovine antibodies and other

factors, which when taken with meals bind to diarhoea-causing bacteria and prevent colonization and the pathology associated with

travellers' diarrhoea. In Australia Travelan is approved by the Therapeutic Goods Administration (TGA)

as a listed medicine on the Australian Register of Therapeutic Goods (AUST L106709) and is indicated to reduce the risk of travellers'

diarrhoea and associated symptoms of minor gastrointestinal disorders. In the USA Travelan is sold as a dietary

supplement in accordance with section 403 (r)(6) of the Federal Drug Administration (FDA).

press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of

1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to,

any statements relating to our growth strategy and product development programs and any other statements that are not historical

facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties

that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual

results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain,

perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and

development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical

and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the

early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual

property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking

to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations

or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.